



This open access document is posted as a preprint in the Beilstein Archives at <https://doi.org/10.3762/bxiv.2021.67.v1> and is considered to be an early communication for feedback before peer review. Before citing this document, please check if a final, peer-reviewed version has been published.

This document is not formatted, has not undergone copyediting or typesetting, and may contain errors, unsubstantiated scientific claims or preliminary data.

**Preprint Title** Synthesis, characterization, and cytotoxic evaluation of iron oxide nanoparticles functionalized with galactomannan

**Authors** Francisco R. S. Mendes, Fernanda N. Rodrigues, Nidyedja G. G. Gonçalves, Mateus T. Aerre, Kelvi W. E. Miranda, Francisco F. Bezerra, Paulo A. S. Mourão, Ana C. O. Monteiro-Moreira, Maria S. R. Bastos, Huai N. Cheng, Atanu Biswas, Antônio C. H. Barreto, Hércio S. dos Santos, Alexandre M. R. Teixeira and Renato A. Moreira

**Publication Date** 24 Sep 2021

**Article Type** Full Research Paper

**Supporting Information File 1** Supplementary Material\_FeNP\_Gal\_S\_BJNANO.docx; 278.9 KB

**ORCID® iDs** Francisco R. S. Mendes - <https://orcid.org/0000-0001-8357-6707>; Fernanda N. Rodrigues - <https://orcid.org/0000-0001-6099-0008>; Nidyedja G. G. Gonçalves - <https://orcid.org/0000-0002-7416-1005>; Kelvi W. E. Miranda - <https://orcid.org/0000-0002-5932-4996>; Ana C. O. Monteiro-Moreira - <https://orcid.org/0000-0002-3606-6808>; Huai N. Cheng - <https://orcid.org/0000-0001-8647-057X>; Antônio C. H. Barreto - <https://orcid.org/0000-0002-5757-334X>; Hércio S. dos Santos - <https://orcid.org/0000-0001-5527-164X>; Alexandre M. R. Teixeira - <https://orcid.org/0000-0001-6786-2076>

License and Terms: This document is copyright 2021 the Author(s); licensee Beilstein-Institut.

This is an open access work under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0>). Please note that the reuse, redistribution and reproduction in particular requires that the author(s) and source are credited and that individual graphics may be subject to special legal provisions.

The license is subject to the Beilstein Archives terms and conditions: <https://www.beilstein-archives.org/xiv/terms>.

The definitive version of this work can be found at <https://doi.org/10.3762/bxiv.2021.67.v1>

# **Synthesis, characterization, and cytotoxic evaluation of iron oxide nanoparticles functionalized with galactomannan**

Francisco R.S. Mendes<sup>1,9</sup>, Fernanda N. Rodrigues<sup>4</sup>, Nidyedja G.G. Gonçalves<sup>4</sup>, Mateus T. Aerre<sup>3</sup>, Kelvi W.E. Miranda<sup>5</sup>, Francisco F. Bezerra<sup>6</sup>, Paulo A. S. Mourão<sup>6</sup>, Ana C.O. Monteiro-Moreira<sup>1,3</sup>, Maria S.R. Bastos<sup>2</sup>, Huai N. Cheng<sup>7</sup>, Atanu Biswas<sup>8</sup>, Antônio C.H. Barreto<sup>10</sup>, Hércio S. dos Santos<sup>1,9</sup>, Alexandre M.R. Teixeira<sup>1, \*9</sup>, Renato A. Moreira<sup>1,3,4</sup>

Address: <sup>1</sup> Graduate Program in Biotechnology, Northeast Biotechnology Network, State University of Ceará, Campus Itaperi, Fortaleza, CE, Brazil.

<sup>2</sup> Food Packaging Technology Laboratory, Embrapa Agroindústria Tropical, Fortaleza, CE, Brazil.

<sup>3</sup> Centre of Experimental Biology (NuBEx), University of Fortaleza, Fortaleza, CE, Brazil.

<sup>4</sup> Department Biochemistry and Molecular Biology, Federal University of Ceará, Fortaleza, CE, Brazil.

<sup>5</sup> Graduate Program in Biomaterials Engineering, Federal University of Lavras, Lavras, MG, Brazil.

<sup>6</sup> Institute of Medical Biochemistry Leopoldo de Meis, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, 21941-913 Rio de Janeiro, RJ, Brazil.

<sup>7</sup> USDA Agricultural Research Service, Southern Regional Research Center, 1100 Robert E. Lee Blvd., New Orleans, LA 70124, USA.

<sup>8</sup> USDA Agricultural Research Service, National Center for Agricultural Utilization Research, 1815 N. University St., Peoria, IL 61604, USA.

<sup>9</sup> Graduate Program in Biological Chemistry, Department of Biological Chemistry, Regional University of Cariri, Crato, CE, Brazil.

<sup>10</sup> Department of Physics, Federal University of Ceará, Fortaleza, CE, Brazil.

Email: Alexandre M.R. Teixeira – alexandre.teixeira@urca.br

\* Corresponding author

## 33 **Abstract**

34 Iron nanoparticles (FeNP) present excellent magnetic properties and chemical stability,  
35 and for this reason, they are often configured into materials for a variety of potential  
36 uses in medical, biotechnological, and other applications. In this work, iron oxide  
37 nanoparticles functionalized with galactomannan (FeNP/Gal) from *Caesalpinia*  
38 *pulcherrima* were synthesized and submitted to characterization and evaluation of the  
39 cytotoxic activity. The functionalized nanoparticles were synthesized by co-  
40 precipitation and subjected to a process of surface modification with galactomannan  
41 and epichlorohydrin. These nanomaterials were characterized using infrared  
42 spectroscopy, X-ray diffraction (XRD), thermogravimetric analysis (TGA), differential  
43 thermogravimetric analysis (DTA), and scanning electron microscopy (SEM). 1D and  
44 2D nuclear magnetic resonance (NMR) spectroscopy were also used in the structural  
45 analysis of the galactomannan. In addition, *in vitro* study was carried out to evaluate  
46 the cytotoxic activity of the FeNP/Gal nanoparticles on human cells of the HEK-293  
47 strain (ATCC® CRL-1573). The FeNP/Gal nanoparticles had an average diameter of  
48  $13 \pm 2$  nm as opposed to  $11 \pm 2$  nm for unreacted FeNP. The infrared spectrum of the  
49 FeNP/Gal nanoparticles presents characteristic absorbance bands of their chemical  
50 constituents, confirming that the iron oxide nanoparticles were functionalized with  
51 galactomannan. The cytotoxicity assay for the FeNP/Gal nanoparticles did not show  
52 significant cytotoxicity against HEK 293-Human embryonic kidney cell lines below 800  
53  $\mu\text{g/mL}$ . However, this study points out the possibility of using hemicellulose and other  
54 plant-based polysaccharides to produce nanostructured materials for tissue  
55 engineering and other biomedical applications.

## 56 **Keywords**

57 Functionalized nanoparticles; Galactomannan; XRD; TGA; DTA; SEM.

## 58 **Introduction**

59 Nanoparticles of inorganic materials have been the focus of recent research attention  
60 due to their magnetic properties, chemical stability, and structural dimensions that  
61 render them suitable for medical and biotechnological applications [1]. These  
62 nanomaterials have been shown to be useful in microfluidics [2], photonics [3], Li-ion  
63 batteries, catalysis [1], chemical sensors [4], magnetic separation [5], and biomedical  
64 applications [6].

65 Magnetic iron oxides (e.g.,  $\text{Fe}_3\text{O}_4$  and  $\gamma\text{-Fe}_2\text{O}_3$ ) with different nanostructures are  
66 involved in biomedicine, such as contrast agents in magnetic resonance, drug release  
67 agents, and specific materials for cell imaging and biomedical treatments [7]. More  
68 specifically, these innovative materials are considered model systems for fluid  
69 magnetic hyperthermia in the treatment of cancer. For chemotherapy and  
70 radiotherapy, their properties, such as superparamagnetism and chemical stability, are  
71 especially beneficial [7]. Nonetheless, biocompatibility and biodegradability of the  
72 materials used are potentially important for applications in the fields of biomedicine and  
73 tissue engineering [5, 6].

74 *Caesalpinia pulcherrima* of the genus *Caesalpinia* belongs to the family Leguminosae-  
75 Caesalpinioideae and is popularly known as flamboyant-de-jardin or flamboianzinho  
76 [8]. This species has the shape of a woody shrub, and its fruit has a variant size of  
77 about 6 to 12 cm in length [8]. This plant multiplies itself with seeds, which are  
78 produced in the semiarid region of Northeast Brazil, mainly in the state of Ceará [9].  
79 The seeds are rich in galactomannan (a type of hemicellulose), which has a chemical

80 structure consisting of a main chain of D-mannopyranose linked together with  $\beta$ - (1  $\rightarrow$   
81 4) bonds, with branches of D-galactopyranose linked via  $\alpha$ -(1  $\rightarrow$  6) onto the main-chain  
82 mannopyranose [10-12]. This biopolymer seems promising for use in controlled drug  
83 release [13, 14]. For water-soluble drugs, the release of the drug can be controlled  
84 according to the degree of cross-linking in this biopolymer [15]. In addition, it has been  
85 used in the formulation of hydrogels and cross-linking of membranes for wound healing  
86 [16], as well as in the development of new food packaging materials [11, 17]. The  
87 galactomannans are sustainable, biodegradable, and ecofriendly polymers that can be  
88 combined with magnetic nanomaterials in order to reduce the toxicity of the  
89 nanomaterials [18].

90 In view of the above considerations, the present work was aimed to synthesize iron  
91 oxide nanoparticles and functionalize them with the hemicellulose biopolymer  
92 extracted from the seeds of *Caesalpinia pulcherrima*. These functionalized  
93 nanoparticles were then characterized and evaluated for *in vitro* cytotoxicity, using  
94 normal human HEK-293 cells (ATCC<sup>®</sup> CRL-1573).

## 95 **Results and Discussion**

### 96 **Biopolymer extraction and characterization**

97 The extraction yield of the polysaccharide from the seeds was expressed as the  
98 percentage of dry weight obtained after extraction in relation to the dry weight of the  
99 seeds [19]. The extraction of galactomannan from *C. pulcherrima* showed a yield of  
100 25% (w/w) in relation to the seed weight. The literature reported similar results for the  
101 extraction of biopolymers in seeds of *G. triacanthos* and *C. pulcherrima*, which showed  
102 yields of 24.73% and 25%, respectively [11, 20].

103 The galactomannan showed a Mw of  $4.3 \times 10^6$  g.mol<sup>-1</sup> and a Mn of  $3.8 \times 10^5$  g.mol<sup>-1</sup>.  
104 In earlier work, the molecular weights were shown to be  $1.34 \times 10^7$  [12]. The Mw/Mn  
105 polydispersity was 11.3. During the synthesis of this biopolymer, the mannosyl  
106 transferase enzyme influenced and regulated the size of the biopolymer chain [21].  
107 The <sup>1</sup>H NMR and <sup>1</sup>H-<sup>13</sup>C HSQC spectra of the galactomannan are shown in Figures  
108 S1 and S2 of the Supplementary Material, respectively. The NMR data are consistent  
109 with the galactomannan structure, with the <sup>1</sup>H and <sup>13</sup>C peaks assigned in the figure.  
110 The ratio of galactose : mannose appears to be about 1: 1.8 [11]. Thus, this  
111 galactomannan is similar to guar gum, which is approved for use as a thickener and  
112 stabilizer in food and feed formulations.


### 113 **Characterization of nanoparticles**

114 In order to evaluate the functionalization of inorganic materials by organic molecules,  
115 such as biopolymers, different analytical techniques need to be used [22]. The surface  
116 modification of the nanoparticles can be seen in the IR spectra, shown in Figure 1.  
117 The unmodified iron oxide nanoparticle (FeNP) spectrum shows wide bands at 3400-  
118 3030 cm<sup>-1</sup> for O-H stretching [23, 24] and a relatively narrow 1624 cm<sup>-1</sup> band attributed  
119 to the bending vibrations for the water molecules coordinated with Fe atoms on the  
120 surface [23, 24]. The bands at <700 cm<sup>-1</sup> are all due to the vibrations of Fe-O bonds.  
121 For example, the band at 630-550 cm<sup>-1</sup> can be attributed to the vibrations of Fe-O  
122 bonds of iron oxide in the tetrahedral and octahedral structures of the Fe<sub>3</sub>O<sub>4</sub> crystals  
123 [23]. The 432 cm<sup>-1</sup> band is due to the octahedral site and corresponds to the Fe-O  
124 bond of the magnetite [23, 25].

125

126

127




128  
 129 **Figure 1:** FT-IR spectra of the samples of galactomannan (Gal), iron nanoparticles  
 130 (FeNP) and iron nanoparticles functionalized with galactomannan (FeNP/Gal).  
 131

132 The FT-IR spectrum of the samples of galactomannan (Gal) (Figure 1, top) shows an  
 133 intense absorption band at  $3340\text{ cm}^{-1}$  assigned to the O-H stretching vibration [26, 27].  
 134 The band at  $2884\text{ cm}^{-1}$  can be attributed to the C-H symmetric and asymmetric  
 135 vibrations [26, 27]. The band at  $1639\text{ cm}^{-1}$  is due to the residual water present [28]  
 136 and possibly  $\text{COO}^-$  asymmetric stretching [29]. The intense band at  $1058\text{ cm}^{-1}$  is  
 137 associated with the vibrations of C-O-C in the pyranose ring [30]. The bands at  $872$   
 138 and  $810\text{ cm}^{-1}$  correspond to the stretching in the anomeric conformations  $\beta$ -D-  
 139 mannopyranose and  $\alpha$ -D-galactopyranose, respectively [26, 27, 30].

140 The FT-IR spectrum of FeNP/Gal nanoparticles (Figure 1, bottom) provides the  
 141 imprints of the chemical reactions involved. In the region  $1300\text{-}4000\text{ cm}^{-1}$ , the IR  
 142 spectrum is somewhat similar to that of epichlorohydrin itself [31], but below  $1300\text{ cm}^{-1}$

143 <sup>1</sup>, the bands corresponding to epichlorohydrin are much diminished in intensities,  
 144 suggesting that a part of the epichlorohydrin has reacted. Even better understanding  
 145 can be obtained by a comparison with the FT-IR spectra of epichlorohydrin, ethylene  
 146 oxide, and 1,2-dichloroethane [31] and the earlier assignments for epichlorohydrin as  
 147 published in the literature [32, 33]. Thus, the bands at 3119 and 3000  $\text{cm}^{-1}$  are due to  
 148 epoxide vibrations of the C-H stretching modes, and the band at 1389  $\text{cm}^{-1}$  may be  
 149 attributed to  $\text{CH}_2\text{Cl}$  deformations. The band at 550  $\text{cm}^{-1}$  confirms the presence of iron  
 150 oxide; the absence of the OH bands at 3200-3500  $\text{cm}^{-1}$  suggests that the OH groups  
 151 on iron oxide have mostly reacted with epichlorohydrin or Gal. The band at 1755  $\text{cm}^{-1}$   
 152 (for carbonyl functionalities) suggests that perhaps some of the epoxides have been  
 153 rearranged to carbonyl functionalities [34, 35]. The band at 2802  $\text{cm}^{-1}$  and the small  
 154 band at 1050  $\text{cm}^{-1}$  indicates the presence of galactomannan that is attached to iron  
 155 oxide or epichlorohydrin residues, but the absence of the OH band at 3340  $\text{cm}^{-1}$   
 156 suggests that the amount of galactomannan is either relatively low and/or that the OH  
 157 in galactomannan has mostly reacted with epichlorohydrin or iron oxide. An  
 158 approximate reaction scheme below roughly captures the situation:

159



160

161

162 **Scheme 1.** Reaction pathways where iron oxide ( $\text{Fe}_x\text{O}_y$ ) was formed in situ, in the  
 163 presence of epichlorohydrin (ECH) and galactomannan (Gal).

164



165 Note that the IR spectrum observed for FeNP/Gal in this work is different from the  
166 spectra reported earlier for iron oxide nanoparticles coated with dextran [36, 37]. In  
167 those cases, the dextran was reacted with epichlorohydrin and NaOH, which caused  
168 cross-linking of the dextran. In our reaction of Gal with epichlorohydrin, NaOH was not  
169 used. As a result, less Gal was incorporated in the FeNP/Gal nanoparticles, and less  
170 cross-linking took place. Our method was designed under conditions such that the  
171 reaction medium promoted FeNP synthesis and functionalization in one step.

172 Dynamic light scattering (DLS) can be used to determine the average size of the  
173 nanoparticles in the liquid phase, based on the Brownian motion of the particles, which  
174 is inversely proportional to the particle diameter [38]. **Table 1** shows the average  
175 diameters of 240 nm (for FeNP), 332 nm (for FeNP/Gal), and 182 nm (for Gal). The  
176 sizes for all three materials exhibited Gaussian distributions (results not shown). The  
177 increase in particle size observed for FeNP/Gal relative to FeNP was due to the  
178 reactions of Gal and epichlorohydrin on iron oxide and the possible formation of  
179 aggregates between the magnetic nanoparticles and the biopolymer, although  
180 intermolecular hydrogen bonding [39] and intermolecular forces [40] (e.g., Van der  
181 Waals, capillary and electrostatic forces) can also be active in the aqueous medium  
182 [39-41].

183 **Table 1:** Size of iron oxide nanoparticles produced from co-precipitation measured by  
184 dynamic light scattering (DLS) and zeta potential ( $\zeta$ ).


Treatment	Average diameter (nm)	$\zeta$ (mV)
Gal	182.0 $\pm$ 0.2*	-12.20 $\pm$ 1.7
FeNP	240.0 $\pm$ 12.0	16.70 $\pm$ 0.80
FeNP/Gal	332.0 $\pm$ 38.0	-30.00 $\pm$ 1.40

190 \* Hydrodynamic radius (HR).

191 Table 1 also gives the zeta potential ( $\zeta$ ):  $16.70 \pm 0.8$  mV (for FeNP),  $-12.20 \pm 1.7$  (for  
192 Gal) and  $-30.00 \pm 1.40$  mV (for FeNP/Gal). FeNP/Gal showed an increase in stability  
193 in an aqueous solution relative to FeNP and Gal solution [25, 42]. This confirms the  
194 presence of some carboxylic groups possibly formed during the drying step during the  
195 preparation of the material. In this case, a shoulder band at  $1700 \text{ cm}^{-1}$  was observed  
196 in the IR, corresponding to COO asymmetric stretching [29]. Thus, the surface of the  
197 nanoparticles was at least partly covered by galactomannan.

198 X-ray diffraction is a technique used to determine the structural properties of many  
199 organic and inorganic materials [43]. It allows the identification of crystalline  
200 compounds, network parameters, crystalline grain size, and preferred orientation and  
201 degree of crystallinity of the materials [43, 44]. The galactomannan diffractogram,  
202 Figure 2A, shows an amorphous structure. However, it also contains a small amount  
203 of partially crystalline regions formed by the packing of mannan chains in the less  
204 substituted regions of the biopolymer [26].

205



206

207 **Figure 2:** XRD diffractograms of the samples (A) Gal, (B) FeNP, and (C) FeNP/Gal.

208

209 The FeNP diffractogram, Figure 2B, shows that the nanomaterial is crystalline.

210 In the literature, the direction of crystallite growth is along the planes that are

211 characteristically observed in iron oxide (220), (311), (222), (400), (422), (511), (440),

212 (620), and (533) [45]. The diffraction peaks are consistent with the observations made

213 in the IR spectrum (Figure 1) for Fe<sub>3</sub>O<sub>4</sub> nanoparticles with the presence of peaks

214 characteristic of the vibrations at 600-550 cm<sup>-1</sup>. Thus, the XRD data are consistent with

215 the presence of magnetite, confirmed by the peaks at (220) and (311) [46]. The XRD

216 pattern is very close to the reported data in JCPDS 65-3107 [47].

217 In Figure 2C, the iron nanoparticles reacted with galactomannan and  
218 epichlorohydrin show broadening of the diffraction peaks for iron oxide, reflecting the  
219 coating of the magnetic nanoparticle with organic materials. In this case, the  
220 diffractogram for FeNP remained essentially unchanged after galactomannan-  
221 epichlorohydrin reaction, e.g., the diffraction peaks at (220), (311), (400), (422), (511),  
222 and (440), which are characteristic of  $\text{Fe}_2\text{O}_3$ . Furthermore, all the peaks shown  
223 suggested a mixture of maghemite  $\text{Fe}_2\text{O}_3$ , residual  $\gamma\text{-Fe}_2\text{O}_3$ , and magnetite  $\text{Fe}_3\text{O}_4$  [45].  
224 The observation can be attributed to the fact that magnetite and maghemite have a  
225 cubic structure with very similar network parameters [48]. The efficient coating process  
226 on iron oxide nanoparticles can be seen in Figure 2, where the contribution of  
227 amorphous areas causes enlargements and reductions of intensities in most peaks.  
228 Moreover, the amorphization causes some displacements of the peaks, as observed  
229 at  $2\theta = 43.4^\circ$  and  $63.0^\circ$ , which shift to  $2\theta = 44^\circ$  and  $64^\circ$ ). However, the diffractogram  
230 does not present any loss of nanomaterial crystallinity, indicating that the internal  
231 structure of FeNP is maintained. Therefore, DLS data together with XRD result confirm  
232 that the nanoparticles are coated with galactomannan and epichlorohydrin derivatives.  
233 The thermal properties of the materials have been evaluated by TGA. With this  
234 technique, we can determine the composition of FeNP/Gal and possible interactions  
235 of the components [49]. Figure 3 shows the thermal degradation of FeNP, Gal, and  
236 FeNP/Gal, which displays two or more main weight-loss stages from 25 to 700 °C.

237


238

239

240

241

242



244


245 **Figure 3:** (A) Thermogravimetric curves for Gal, FeNP and FeNP/Gal, and (B)  
 246 differential thermogravimetric curves for the same samples.

247 In the first stage, the loss of weight is mainly due to the elimination of water molecules  
 248 absorbed by the material(s) or adsorbed on the surface [50]. The weight losses are  
 249 8.0% (Gal), 4.4% (FeNP), and <0.5% (FeNP/Gal). This result is compatible with the IR  
 250 data, where the water bending vibration was observed at  $1630\text{ cm}^{-1}$  for Gal and FeNP  
 251 (Figure 1). Similar results have been reported earlier [50], where the first stage of the  
 252 thermal curve showed a loss of weight of around 3.0% in iron oxide nanoparticles at  
 253 about  $180\text{ }^{\circ}\text{C}$ . In the second stage, weight losses of 64% and 48% were found for Gal  
 254 and FeNP/Gal at  $286\text{ }^{\circ}\text{C}$  and  $190\text{ }^{\circ}\text{C}$ , respectively. For Gal, this was due to the  
 255 breakdown of the polysaccharide structure, as shown for similar data for guar gum [51,  
 256 52]. However, in FeNP/Gal, the lower weight-loss temperature was due to the  
 257 degradation of epichlorohydrin residues and Gal-epichlorohydrin residues attached to  
 258 iron oxide, as shown in Scheme 1. In the third stage,  $300\text{-}700^{\circ}\text{C}$ , the degraded Gal  
 259 was converted to aromatic structures and then to biochar. For FeNP/Gal, the weight  
 260 loss at  $> 380^{\circ}\text{C}$  was relatively small (perhaps 4%), suggesting that the Gal content in  
 261 FeNP/Gal was about 15-20%. From the residual weights at  $500^{\circ}\text{C}$ , the amount of iron

262 oxide in FeNP/Gal was about 50%. Thus, the amount of epichlorohydrin residues in  
263 FeNP/Gal was about 30-35%.

264 Microscopic analysis (FEG-SEM) can indicate, with subsequent high-resolution  
265 imaging techniques, the presence of clusters and the nanometric distribution of particle  
266 size [53]. The topography of coated and uncoated iron nanoparticles and the mean  
267 diameters are shown in Figure 4.

268



269

270 **Figure 4:** SEM micrographs for the (A) iron oxide nanoparticles (FeNP), and (B) iron  
271 oxide nanoparticle reacted with galactomannan and epichlorohydrin (FeNP/Gal). It is  
272 shown in the lower left corners are the average particle diameters (mean  $\pm$  standard  
273 deviation,  $n = 100$ ).

274


275 The photomicrographs indicate that the incorporation of the biopolymer on the FeNP  
276 resulted in an increase in diameter. FeNP had a mean diameter of around 11 nm.  
277 Similar results were observed in the literature, with the core diameter ranging from 10  
278 to 20 nm [54]. With the incorporation of the biopolymer, the mean diameter increased  
279 to 13 nm due to the addition of organic matters, as shown in Scheme 1. Furthermore,  
280 the presence of the biopolymer led to the formation of imperfections in the morphology  
281 of the nanoparticles (Figure 4B) and the tendency for cluster formation because the  
282 nanoparticles functioned as small magnets that tended to attract each other.

283 Iron oxide nanoparticles are attractive for biomedical applications because they have  
284 controllable sizes ranging from a few nanometers to tens of nanometers. These  
285 dimensions are smaller or comparable to those of a virus (20-450 nm), a protein (5–50  
286 nm), a gene (2 nm wide and 10–100 nm long), or a cell (10-100  $\mu\text{m}$ ) [55]. Thus, they  
287 can have the potential to enter or interact with a biological entity of interest. By coating  
288 these nanomaterials with biomolecules for connections or interactions with the  
289 biological entity, we have an additional tool to control or modify these interactions [56,  
290 57].

### 291 **Cytotoxicological assay of nanoparticles for HEK-293**

292 FeNP and FeNP/Gal samples did not show a significant effect ( $p = 0.0377$ ) on cell  
293 viability of the HEK-293 strain below the concentration of 800  $\mu\text{g}/\text{mL}$  (Figure 5). For  
294 both nanoparticles at the tested concentrations, there was no significant difference in  
295 cell viability at concentrations greater than 25  $\mu\text{g}\cdot\text{mL}^{-1}$ . It is important to note that, at  
296 the concentrations evaluated, the nanoparticles in the culture medium did not interfere  
297 with the fluorescence readings. FeNP and FeNP/Gal exhibited an inhibitory  
298 concentration at 50% inhibition ( $\text{IC}_{50}$ ) above 800  $\mu\text{g}\cdot\text{mL}^{-1}$ .

299



300  
301  
302  
303  
304  
305

**Figure 5:** Viability of HEK-293 cells incubated with iron nanoparticles (FeNP) and iron nanoparticles with galactomannan (FeNP/Gal) at concentrations of 12.5 to 800 µg.mL<sup>-1</sup>. Each value represents the mean ± standard error of the mean (E.P.M.)

306 Earlier studies showed that the mechanism of action of iron oxide nanoparticles is  
307 linked to the generation of reactive oxygen species (ROS), which can result in  
308 inflammatory processes in the cells and consequent rupture in the mitochondrial  
309 membrane, DNA damage, and programmed cell death due to apoptosis [58, 59].  
310 However, the present result can be rationalized by the fact that the reactions caused  
311 by the iron ions generated by the dissociation of NPs in the cell cytoplasm are  
312 controlled by a complex of proteins that can transport or store this nanomaterial,  
313 thereby providing for the cell tolerance of FeNP.



## 314 **Conclusion**

315 The reaction of the iron oxide nanoparticles with epichlorohydrin and galactomannan  
316 (FeNP/Gal) was performed successfully. The reaction procedure for these iron  
317 nanoparticles is easy to use and can be scaled up to the production levels. The infrared  
318 spectrum of the FeNP/Gal nanoparticles presents characteristic absorbance bands of  
319 their chemical constituents, confirming that the iron oxide nanoparticles were  
320 functionalized with galactomannan. The nanoparticles obtained did not show  
321 cytotoxicity against the normal human cell line at the concentrations evaluated. The  
322 reaction with epichlorohydrin and galactomannan did not significantly change the  
323 morphology of the FeNP, increasing its mean diameter from  $11 \pm 2$  nm to  $13 \pm 2$  nm.  
324 The results of this work suggest that the FeNP/Gal can be used as a biomedical  
325 nanomaterial for many applications, e.g., direct surface contact with pathogenic micro-  
326 organisms, prevention or disruption of the formation of biofilms on devices, and  
327 environment/medical diagnostics. Moreover, this approach opens a new window for  
328 the design of magnetic nanoparticles in tissue engineering and other biomaterials  
329 through the choice of pertinent plant biopolymers and the modified coating procedure.

## 330 **Experimental**

### 331 **Materials**

332 Iron (III) chloride hexahydrate, iron (II) chloride heptahydrate, ammonium hydroxide  
333 (28–30%), and acetone (ACS reagent grade) were acquired from Sigma Aldrich  
334 Company, Milwaukee, WI, USA.

## 335 **Extraction and characterization of biopolymer**

336 The extraction of galactomannan was adapted from the procedure described by  
337 Cerqueira *et al.* [19]. Seeds were removed from the pods, cleaned, placed in a blender,  
338 and mechanically broken. Afterward, the endosperm was manually separated from the  
339 germ and the hull. The endosperm obtained was suspended in 96% ethanol (w/w) in a  
340 proportion of 1:3 (seeds: ethanol) at 70 °C for 20 min to inactivate the enzymes and  
341 eliminate the low-molecular-weight compounds. The ethanol was removed, and  
342 distilled water was added in a 1:10 (endosperm: water) proportion, and the suspension  
343 was left overnight. The next day, the amount of water was refilled to an endosperm:  
344 water ratio of 1:10 and mixed in a blender for 5 min. Next, the viscous solution was  
345 filtered through a nylon net and precipitated by adding 96:4 ethanol:water at a weight  
346 ratio of 1:2. The precipitate was successively washed with acetone, dried with hot air,  
347 and milled.

348 The molecular weights ( $M_n$  and  $M_w$ ) of the biopolymer was determined by gel  
349 permeation chromatography (GPC) (Shimadzu Model LC-20AD, Kyoto, Japan) using a  
350 PolySep linear column (7.8 x 300 mm, Waters, Milford, MA, USA), flow rate of 1.0  
351 mL.min<sup>-1</sup>, biopolymer concentration of 1 mg.mL<sup>-1</sup>, and 0.1 mol.L<sup>-1</sup> NaNO<sub>3</sub> in water as  
352 the eluent. The elution volume was corrected using ethylene glycol as an internal  
353 marker at 11.25 mL. The GPC was calibrated with pullulan samples (Shodex, Showa  
354 Denko, Kawasaki, Japan) as standards. All analyses were conducted at room  
355 temperature. A Waters Model RID-10A (Milford, MA, USA) was used as the refractive  
356 index detector. The polydispersity value was calculated via  $M_w/M_n$  [11].

357 NMR spectra (1D and 2D) were acquired using 2.5% (w/v) solutions in D<sub>2</sub>O on an  
358 Avance DRX 500 spectrometer (Bruker, Billerica, MA, USA). For the 2D <sup>1</sup>H-<sup>13</sup>C HSQC  
359 experiment, we used 128 scans, 1024 x 256 points, GARP pulse decoupling, and a 2s

360 delay time between scans. For 2D  $^1\text{H}$ - $^1\text{H}$  NOESY spectra, 32 scans, 2048 x 512 points,  
361 and a 2s delay time between scans were used. The analysis was performed at a probe  
362 temperature of 323K using tetramethylsilane (TMS) as external reference (0.00 ppm).  
363

### 364 **Synthesis of nanoparticles by co-precipitation**

365 Magnetic iron oxide nanoparticles (FeNP) were prepared by alkaline co-precipitation  
366 of ferrous chloride tetrahydrate,  $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$  (1.34 g), and ferric chloride hexahydrate  
367  $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$  (3.40 g) at a 1:2 ratio. The salts were dissolved in 150 mL deionized water  
368 in a three-necked glass flask, which was placed in a heating mantle with a magnetic  
369 stirrer. When the salt solution was vigorously stirred at 70 °C, ammonium hydroxide  
370 ( $\text{NH}_4\text{OH}$ ) was added to the system dropwise. The black precipitate was washed with  
371 deionized water until the solution pH was 7.0. The solution was then centrifuged at  
372 5000 rpm for 30 min. The precipitates were collected and dried in an oven at 50 °C for  
373 12 h [6].

### 374 **Synthesis of galactomannan-coated magnetic iron oxide** 375 **nanoparticles**

376 Galactomannan-coated magnetic iron oxide nanoparticles (FeNP/Gal) were  
377 synthesized by the co-precipitation of Fe (II) and Fe (III) in the presence of 2 mL of  
378 epichlorohydrin molecules. Thus, 1.34 g  $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$  and 3.40 g  $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$  were  
379 dissolved in 100 ml of deionized water. Then 1 g of galactomannan previously  
380 dissolved in solution was added together with 2 mL epichlorohydrin. The final solution  
381 was then vigorously stirred at 2,000 rpm at 70 °C for 1 h. In the next step,  $\text{NH}_4\text{OH}$   
382 solution at a concentration of 4 mol.L<sup>-1</sup> was added slowly to produce small-sized  
383 nanoparticles. The resulting dispersion was stirred at 2,000 rpm at 70 °C for 1 h. The  
384 colloidal galactomannan-coated magnetic  $\text{Fe}_3\text{O}_4$  nanoparticles were washed with

385 deionized water:ethanol solution in three stages at ratios of 50:50, 25:75, and 0:100.  
386 These were dehydrated with acetone and dried in an oven at 50 °C for 12 h. All samples  
387 were stored at room temperature.

## 388 **Characterization of nanoparticles**

389 Fourier Transform-infrared spectroscopy (FT-IR) was conducted with a Model Vertex  
390 instrument (Bruker, Ettlingen, Germany). The spectra were recorded in the attenuated  
391 total reflectance (ATR) mode by averaging 32 scans at a spectral range from 4000 to  
392 400  $\text{cm}^{-1}$  and a resolution of 4  $\text{cm}^{-1}$ .

393 X-ray diffraction (XRD) characterization was achieved with a Rigaku Model RU 200R  
394 diffractometer (Rigaku Corp., Tokyo, Japan), using a  $\text{Cu K}\alpha$  ( $\lambda = 1.54 \text{ \AA}$ ) x-ray at 30 kV  
395 and 30 mA in the angular range  $2\theta = 25^\circ - 70^\circ$ , and a step size of  $2^\circ \cdot \text{min}^{-1}$ .

396 A JSM 6701F field-emission scanning electron microscope (FEG-SEM, JEOL, USA)  
397 was used to obtain micrographs of nanoparticles. Average nanoparticle diameters  
398 were measured using the ImageJ software (National Institutes of Health, Bethesda,  
399 MD, USA) from at least 100 measurements of randomly selected nanoparticles.

400 Thermogravimetric analysis (TGA) was conducted on the Gal, FeNP, and FeNP/Gal  
401 samples using an analyzer from TA Instruments, model TGA Q500 V6.7 Build 203  
402 (New Castle, DE, USA). Approximately 10 mg of each sample was placed in a platinum  
403 pan heated over a temperature range of 25-700 °C at  $10^\circ \text{C} \cdot \text{min}^{-1}$  under an oxidative  
404 atmosphere (60:40  $\text{N}_2/\text{air}$ ).

## 405 **Biological activity**

### 406 **Cell culture**

407 The strain used for the cytotoxicity assay was HEK-293 (ATCC® CRL-1573) from  
408 human embryo renal cells. The cells were cultured in 250-mL flasks with Dulbecco's

409 Modified Eagle Medium (DMEM) from Thermo Fisher Scientific (Waltham, MA, USA)  
410 supplemented with 10% fetal bovine serum and 1% solution of antibiotics (penicillin  
411  $100 \text{ U.mL}^{-1}$  and streptomycin  $100 \mu\text{g.mL}^{-1}$ ) obtained from Sigma Aldrich Company  
412 (Milwaukee, WI, USA). The cells were incubated in a  $\text{CO}_2$  oven at  $37 \text{ }^\circ\text{C}$  with an  
413 atmosphere of 5%  $\text{CO}_2$  and 95% humidity and periodically observed with the aid of an  
414 inverted microscope.

#### 415 **Cytotoxicity assay with Alamar Blue (resazurin)**

416 The alamar blue assay was used to assess the cell viability of HEK-293 cells (obtained  
417 from the Cell Bank of Rio de Janeiro, RJ, Brazil) against FeNP and FeNP/Gal samples.  
418 The cells in logarithmic growth were seeded in 96-well plates at a density of  $10^5$   
419  $\text{cells.mL}^{-1}$ . Then  $100 \mu\text{L.well}^{-1}$  were applied and incubated for 24 h in an oven with an  
420 atmosphere of 5%  $\text{CO}_2$ , 95% relative humidity under  $37 \text{ }^\circ\text{C}$ .

421 The FeNP and FeNP/Gal nanoparticles were autoclaved at  $121 \text{ }^\circ\text{C}$  for 15 min to rule  
422 out microbiological contamination.  $1 \mu\text{L}$  of the stock solution of each sample was  
423 removed and diluted directly in a serial manner in the complete DMEM medium. The  
424 tested concentrations ranged from 12.5 to  $800 \mu\text{g.mL}^{-1}$ . Cell viability control (CTL) was  
425 represented by the complete culture medium. Wells containing only medium and  
426 sample were evaluated for possible interference with the fluorescence reading. After  
427 applying the samples, the plates were incubated at  $37 \text{ }^\circ\text{C}$  for 72 h, with an atmosphere  
428 of 5%  $\text{CO}_2$  and 95% humidity. In addition, before the end of the incubation period, 10  
429  $\mu\text{L}$  of the  $0.312 \text{ mg.mL}^{-1}$  Alamar Blue solution (Sigma-Aldrich, San Louis, Missouri,  
430 USA) was added to each well. After a fixed time, the fluorescence was measured with  
431 the aid of the ELISA reader (BioTek Synergy HT, UK) using an excitation wavelength  
432 at 530-560 nm and emission at 590 nm. Cell viability (%) was calculated using Equation  
433 (1):

434

$$435 \quad Viability (\%) = \left( \frac{RFU_{treated}}{RFU_{control}} \right) \times 100 \quad (1)$$

436

437

438 where  $RFU_{treated}$  corresponds to the relative fluorescence units of the wells treated with  
439 the samples, and  $RFU_{control}$  to the relative fluorescence units of the untreated wells.

440

## 441 **Statistical analysis**

442 For cytotoxicity, samples were tested in serial dilutions in triplicate, and the results  
443 were evaluated according to the mean  $\pm$  standard error of the mean (E.P.M.) of the  
444 percentage of cell growth inhibition of  $n$  independent experiments. The data were  
445 analyzed by two-way ANOVA using the GraphPad Prism Software, version 7.03.

## 446 **Supporting Information**

447 Supporting information text

448 Supporting Information File 1: SUPPLEMENTARY MATERIAL

449 File Name: SUPPLEMENTARY MATERIAL

450 File Format: .Docx file was attached as Supplementary Material. It contains the NMR  
451 data which are cited in Figures S1-S2.

452 **Figure S1:**  $^1\text{H}$  NMR of the galactomannan.

453 **Figure S2:**  $^1\text{H}$ - $^{13}\text{C}$  HSQC spectrum of the galactomannan.

## 454 **Acknowledgements**

455 We acknowledge Centro Nacional de Biologia Estrutural e Bioimagem (CENABIO) for  
456 the access to perform the NMR analysis and Dr. K.T. Klasson for helpful discussions.

457 This research was supported in part by the U.S. Department of Agriculture, Agricultural  
458 Research Service. Mention of trade names or commercial products in this publication  
459 is solely for the purpose of providing specific information and does not imply  
460 recommendation or endorsement by the U.S. Department of Agriculture. USDA is an  
461 equal opportunity provider and employer.

## 462 **Funding**

463 Thanks are due to the funders of this research, including Capes, CNPq, Funcap, Finep,  
464 the National Nanotechnology Laboratory Applied to Agribusiness - Embrapa  
465 Instrumentation - São Carlos / SP and Embrapa Agroindústria Tropical, and the  
466 Technological Chemistry Laboratories and Microbiological Control Laboratory at the  
467 University of Fortaleza.

## 468 **References**

- 469 1. Sun, K.; Sun, C.; Tang, S. *CrystEngComm* **2016**, *18* (5), 714-720,  
470 10.1039/C5CE02095F.
- 471 2. Lan, J.; Chen, J.; Li, N.; Ji, X.; Yu, M.; He, Z. *Talanta* **2016**, *151*, 126-131.
- 472 3. Wang, W.; Li, Q.; Zheng, A.; Li, X.; Pan, Z.; Jiang, J.; Zhang, L.; Hong, R.;  
473 Zhuang, L. *Results Phys.* **2019**, *14*, 102366.

- 474 4. Rahman, M. M.; Asiri, A. M. *Sensing and Bio-Sensing Research* **2015**, *4*, 109-  
475 117.
- 476 5. Ezzaier, H.; Marins, J. A.; Claudet, C.; Hemery, G.; Sandre, O.; Kuzhir, P.  
477 *Nanomaterials* **2018**, *8* (8).
- 478 6. Catalano, E.; Di Benedetto, A. *J. Phys. Conf. Ser.* **2017**, *841*, 012010.
- 479 7. Albarqi, H. A.; Wong, L. H.; Schumann, C.; Sabei, F. Y.; Korzun, T.; Li, X.;  
480 Hansen, M. N.; Dhagat, P.; Moses, A. S.; Taratula, O.; Taratula, O. *ACS Nano*  
481 **2019**, *13* (6), 6383-6395.
- 482 8. Lorenzi, H.; Matos, F. J. A. *Plantas Mediciniais no Brasil: nativas e exóticas*  
483 *cultivadas* Instituto Plantarum de Estudos da Flora Ltda.: Brazil - Nova Odessa,  
484 SP, 2002.
- 485 9. Braga, R. C.; Teixeira-Sá, D. M. A.; Ribeiro, A. F.; Miranda, R. L.; Almeida, L.  
486 M. D.; Horta, A. C. G.; Moreira, R. D. A. *Braz. Arch. Biol. Technol.* **2011**, *54* (2),  
487 283-292.
- 488 10. Cerqueira, M. A.; Souza, B. W. S.; Teixeira, J. A.; Vicente, A. A. *Food Hydrocoll.*  
489 **2012**, *27* (1), 175-184.
- 490 11. Mendes, F. R. S.; Bastos, M. S. R.; Mendes, L. G.; Silva, A. R. A.; Sousa, F. D.;  
491 Monteiro-Moreira, A. C. O.; Cheng, H. N.; Biswas, A.; Moreira, R. A. *Food*  
492 *Hydrocoll.* **2017**, *70*, 181-190.
- 493 12. De Sousa, F. D.; Holanda-Araújo, M. L.; Roberto, J.; De Souza, R.; Miranda, R.  
494 D. S.; Almeida, R. R.; Gomes-filho, E.; Pontes-Ricardo, N. M.; Monteiro-  
495 Moreira, A. C. O.; Moreira, R. D. A. *Open Access Library Journal* **2017**, *4*,  
496 e3683.
- 497 13. Silveira, J. L. M.; Bresolin, T. M. B. *Quim. Nova* **2011**, *34* (2), 292-299.



- 498 14. Frota, H. B. M.; Menezes, J.; Siqueira, S.; Ricardo, N.; Araújo, T.; Souza, C.;  
499 Bandeira, P.; Santos, H. *Quim. Nova* **2018**, *41* (5), 544-549.
- 500 15. Jeevanandham, S.; Dhachinamoorthi, D.; Sekhar, K. B. C. *Iran. J. Pharm. Sci.*  
501 **2011**, *Volume 10* (Number 3), 597-603.
- 502 16. de Sousa, F. D.; Vasconcelos, P. D.; da Silva, A. F. B.; Mota, E. F.; da Rocha  
503 Tomé, A.; Mendes, F. R. d. S.; Gomes, A. M. M.; Abraham, D. J.; Shiwen, X.;  
504 Owen, J. S.; Lourenzoni, M. R.; Campos, A. R.; Moreira, R. d. A.; Monteiro-  
505 Moreira, A. C. d. O. *Int. J. Biol. Macromol.* **2019**, *121*, 429-442.
- 506 17. Sousa, A. M. M.; Gonçalves, M. P. *Carbohydr. Polym.* **2015**, *132*, 196-204.
- 507 18. Souza, N. D. G.; Freire, R. M.; Cunha, A. P.; da Silva, M. A. S.; Mazzetto, S. E.;  
508 Sombra, A. S. B.; Denardin, J. C.; Ricardo, N. M. P. S.; Fachine, P. B. A. *MCP*  
509 **2015**, *156*, 113-120.
- 510 19. Cerqueira, M. A.; Pinheiro, A. C.; Souza, B. W. S.; Lima, Á. M. P.; Ribeiro, C.;  
511 Miranda, C.; Teixeira, J. A.; Moreira, R. A.; Coimbra, M. A.; Gonçalves, M. P.;  
512 Vicente, A. A. *Carbohydr. Polym.* **2009**, *75* (3), 408-414.
- 513 20. Cerqueira, M. A.; Lima, Á. M.; Teixeira, J. A.; Moreira, R. A.; Vicente, A. A. *J.*  
514 *Food Eng.* **2009**, *94* (3), 372-378.
- 515 21. Bento, J. F.; Mazzaro, I.; de Almeida Silva, L. M.; de Azevedo Moreira, R.;  
516 Ferreira, M. L. C.; Reicher, F.; de Oliveira Petkowicz, C. L. *Carbohydr. Polym.*  
517 **2013**, *92* (1), 192-199.
- 518 22. Silverstein, R. M. *Spectrometric Identification of Organic Compounds*, 8th  
519 Revised ed. ed.; John Wiley & Sons: 2005.
- 520 23. Ebrahiminezhad, A.; Ghasemi, Y.; Rasoul-Amini, S.; Barar, J.; Davaran, S. *Bull.*  
521 *Korean Chem. Soc.* **2012**, *33* (12), 3957-3962.

- 522 24. Ruíz-Baltazar, A.; Esparza, R.; Rosas, G.; Pérez, R. *J. Nanomater.* **2015**, *2015*,  
523 240948.
- 524 25. El-Guendouz, S.; Aazza, S.; Lyoussi, B.; Bankova, V.; Lourenço, J. P.; Costa,  
525 A. M. R.; Mariano, J. F.; Miguel, M. G.; Faleiro, M. L. *Molecules* **2016**, *21* (9).
- 526 26. Cerqueira, M. A.; Souza, B. W. S.; Simões, J.; Teixeira, J. A.; Domingues, M.  
527 R. M.; Coimbra, M. A.; Vicente, A. A. *Carbohydr. Polym.* **2011**, *83* (1), 179-185.
- 528 27. Pascoal, K. L. L.; Siqueira, S. M. C.; de Amorim, A. F. V.; Ricardo, N. M. P. S.;  
529 de Menezes, J. E. S. A.; da Silva, L. C.; de Araújo, T. G.; Almeida-Neto, F. W.  
530 Q.; Marinho, E. S.; de Moraes, S. M.; Saraiva, G. D.; de Lima-Neto, P.; dos  
531 Santos, H. S.; Teixeira, A. M. R. *J. Mol. Struct.* **2021**, *1239*, 130499.
- 532 28. Kurt, A.; Kahyaoglu, T. *Carbohydr. Polym.* **2014**, *104*, 50-58.
- 533 29. Sato, M. D. F.; Rigoni, D. C.; Canteri, M. H. G.; Petkowicz, C. L. D. O.; Nogueira,  
534 A.; Wosiacki, G. *Acta Sci. Agron.* **2011**, *33* (3).
- 535 30. Figueiró, S. D.; Góes, J. C.; Moreira, R. A.; Sombra, A. S. B. *Carbohydr. Polym.*  
536 **2004**, *56* (3), 313-320.
- 537 31. *NIST, NIST Standard Reference Database Number 69*; 2016.
- 538 32. Kalasinsky, V. F.; Wurrey, C. J. *JRSp* **1980**, *9* (5), 315-323,  
539 <https://doi.org/10.1002/jrs.1250090509>.
- 540 33. Wang, F.; Polavarapu, P. L. *J. Phys. Chem. A* **2000**, *104* (26), 6189-6196.
- 541 34. Ertürk, E.; Göllü, M.; Demir, A. S. *Tetrahedron* **2010**, *66* (13), 2373-2377.

- 542 35. Jat, J. L.; Kumar, G. *Adv. Synth. Catal.* **2019**, 361 (19), 4426-4441,  
543 <https://doi.org/10.1002/adsc.201900392>.
- 544 36. Ali, A. A. A.; Hsu, F.-T.; Hsieh, C.-L.; Shiau, C.-Y.; Chiang, C.-H.; Wei, Z.-H.;  
545 Chen, C.-Y.; Huang, H.-S. *Sci. Rep.* **2016**, 6 (1), 36650.
- 546 37. Unterweger, H.; Subatzus, D.; Tietze, R.; Janko, C.; Poettler, M.; Stiegelschmitt,  
547 A.; Schuster, M.; Maake, C.; Boccaccini, A.; Alexiou, C. *Int. J. Nanomedicine*  
548 **2015**, 6985.
- 549 38. Lim, J.; Yeap, S. P.; Che, H. X.; Low, S. C. *Nanoscale Res. Lett.* **2013**, 8 (1),  
550 381.
- 551 39. McGrath, A. J.; Dolan, C.; Cheong, S.; Herman, D. A. J.; Naysmith, B.; Zong,  
552 F.; Galvosas, P.; Farrand, K. J.; Hermans, I. F.; Brimble, M.; Williams, D. E.; Jin,  
553 J.; Tilley, R. D. *JMMM* **2017**, 439, 251-258.
- 554 40. Gaber, A.; Abdel- Rahim, M. A.; Abdel-Latief, A. Y.; Abdel-Salam, M. N. *Int. J.*  
555 *Electrochem. Sci.* **2014**, 9, 81-95.
- 556 41. Jadhav, S. V.; Nikam, D. S.; Mali, S. S.; Hong, C. K.; Pawar, S. H. *New J. Chem.*  
557 **2014**, 38 (8), 3678-3687, 10.1039/C4NJ00334A.
- 558 42. Vargas, M. A.; Diosa, J. E.; Mosquera, E. *Data in Brief* **2019**, 25, 104183.
- 559 43. Mos, Y. M.; Vermeulen, A. C.; Buisman, C. J. N.; Weijma, J. *GeomJ* **2018**, 35  
560 (6), 511-517.
- 561 44. Huff, W. D. *Clays Clay Miner.* **1990**, 38 (4), 448-448.
- 562 45. Sarkar, A.; Sil, P. C. *Food Chem. Toxicol.* **2014**, 71, 106-115.

- 563 46. Andrade, A. L.; Souza, D. M.; Pereira, M. C.; Fabris, J. D.; Domingues, R. Z.  
564 *Cerâmica* **2009**, *55* (336), 420-424.
- 565 47. Gao, S.; Shi, Y.; Zhang, S.; Jiang, K.; Yang, S.; Li, Z.; Takayama-Muromachi,  
566 E. *J. Phys. Chem. C* **2008**, *112* (28), 10398-10401.
- 567 48. Díaz-Hernández, A.; Gracida, J.; García-Almendárez, B. E.; Regalado, C.;  
568 Núñez, R.; Amaro-Reyes, A. *J. Nanomater.* **2018**, *2018*, 9468574.
- 569 49. Vendruscolo, C. W.; Ferrero, C.; Pineda, E. A. G.; Silveira, J. L. M.; Freitas, R.  
570 A.; Jiménez-Castellanos, M. R.; Bresolin, T. M. B. *Carbohydr. Polym.* **2009**, *76*  
571 (1), 86-93.
- 572 50. Mishra, D.; Arora, R.; Lahiri, S.; Amritphale, S. S.; Chandra, N. *Prot. Met. Phys.*  
573 *Chem. Surf.* **2014**, *50* (5), 628-631.
- 574 51. Mudgil, D.; Barak, S.; Khatkar, B. S. *Int. J. Biol. Macromol.* **2012**, *50* (4), 1035-  
575 1039.
- 576 52. Hongbo, T.; Yanping, L.; Min, S.; Xiguang, W. *Polym. J.* **2012**, *44* (3), 211-216.
- 577 53. Abruzzi, R. C.; Dedavid, B. A.; Pires, M. J. R. *Cerâmica* **2015**, *61* (359), 328-  
578 333.
- 579 54. Hoque, M. A.; Ahmed, M. R.; Rahman, G. T.; Rahman, M. T.; Islam, M. A.; Khan,  
580 M. A.; Hossain, M. K. *Results Phys.* **2018**, *10*, 434-443.
- 581 55. Assa, F.; Jafarizadeh-Malmiri, H.; Ajamein, H.; Anarjan, N.; Vaghari, H.; Sayyar,  
582 Z.; Berenjian, A. *Nano Res.* **2016**, *9* (8), 2203-2225.
- 583 56. Pankhurst, Q. A.; Connolly, J.; Jones, S. K.; Dobson, J. *J. Phys. D: Appl. Phys.*  
584 **2003**, *36* (13), R167-R181.

- 585 57. Bárcena, C.; Sra, A. K.; Gao, J. Applications of Magnetic Nanoparticles in  
586 Biomedicine. In *Nanoscale Magnetic Materials and Applications*; Liu, J. P.;  
587 Fullerton, E.; Gutfleisch, O.; Sellmyer, D. J., Eds.; Springer US: Boston, MA,  
588 2009; pp 591-626.
- 589 58. Koedrith, P.; Boonprasert, R.; Kwon, J. Y.; Kim, I.-S.; Seo, Y. R. *Mol. Cell.*  
590 *Toxicol.* **2014**, *10* (2), 107-126.
- 591 59. Dissanayake, N. M.; Current, K. M.; Obare, S. O. *Int. J. Mol. Sci.* **2015**, *16* (10).  
592